WASHINGTON, D.C. – Elderly men diagnosed with prostate cancer should be discussing with their physicians and family the consequences of the now-confirmed reality that they’ll experience either dementia or alzheimer’s disease if more than 5 doses of testosterone-blocking hormones or orchiectomies are used to treat the life-shortening disease.
This latest information was shared in the July 3, 2019 Journal of the American Medical Association (JAMA) from a researcher’s study of 154, 089 elderly men his team followed for 10 years after they received treatment within two years of a prostate cancer diagnosis. University of Pennsylvania Perelman School of Medicine Research Associate Professor Ravishankar Jayadevappa concluded that deprivation therapy exposure was associated with subsequent diagnosis of Alzheimer disease or dementia over a follow-up period of at least 10 years.
Jayadevappa’s team of researchers set age limits to men 66 and older among the total of 295, 733 men they identified as having been newly-diagnosed with prostate cancer between 1996 and 2003. The “sample” of men whose data the team evaluated was limited to the 154,089 they identified among the aged 66 and older men in the Surveillance, Epidemiology, and End Results (SEER) “fee for service” Medicare Database.
The analyses of the data was conducted between November 1, 2018, and December 31, 2018. The team observed that the National Cancer Institute’s SEER regions have a higher proportion of nonwhite individuals.
Jayadevappa and his team concluded that “clinicians must carefully weigh the long-term risks and benefits of exposure to androgen deprivation therapy in patients with a prolonged life-expectancies.”